Visfatin/NAMPT/PBCEF and Cytokine Concentration in Multiple Sclerosis Patients Compared to Healthy Subjects

Comparison of the Bone Turn-over Markers in Patients with Multiple Sclerosis and Healthy Control Subjects

(2017) A. Hossein-Nezhad et al.   European Journal of Inflammation

Nicotinamide Phosphoribosyl Transferase/Pre-B Cell Colony-Enhancing Factor/Visfatin Is Required for Lymphocyte Development and Cellular Resistance to Genotoxic Stress

(2014) A. Rongvaux et al.   JOURNAL OF IMMUNOLOGY

The Importance of NAD in Multiple Sclerosis

(2009) W. Penberthy et al.   CURRENT PHARMACEUTICAL DESIGN

The analysis of IL-1 beta and its naturally occurring inhibitors in multiple sclerosis: The elevation of IL-1 receptor antagonist and IL-1 receptor type II after steroid therapy

(2009) Irena Dujmovic et al.   JOURNAL OF NEUROIMMUNOLOGY

Pre-B cell colony enhancing factor/NAMPT/visfatin and its role in inflammation-related bone disease

(2009) Alexander R. Moschen et al.   MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS

Multiple sclerosis immunology: The healthy immune system vs the MS immune system

(2009) L. H. Kasper et al.   NEUROLOGY

Catastrophic NAD+ Depletion in Activated T Lymphocytes through Nampt Inhibition Reduces Demyelination and Disability in EAE

(2009) Santina Bruzzone et al.   PLoS One

Interferon-γ, a Th1 Cytokine, Regulates Fat Inflammation

(2008) Viviane Zorzanelli Rocha et al.   CIRCULATION RESEARCH

Models of multiple sclerosis: new insights into pathophysiology and repair

(2008) Hans Lassmann   CURRENT OPINION IN NEUROLOGY